A series of 66 new indolone-N-oxide derivatives was synthesized with three different methods. Compounds were evaluated for in vitro activity against CQ-sensitive (3D7), CQ-resistant (FcB1), and CQ and pyrimethamine cross-resistant (K1) strains of Plasmodium falciparum (P.f.), as well as for cytotoxic concentration (CC 50 ) on MCF7 and KB human tumor cell lines. Compound 26 (5-methoxy-indolone-N-oxide analogue) had the most potent antiplasmodial activity in vitro (<3 nM on FcB1 and = 1.7 nM on 3D7) with a very satisfactory selectivity index (CC 50 MCF7/IC 50 FcB1: 14623; CC 50 KB/IC 50 3D7: 198823). In in vivo experiments, compound 1 (dioxymethylene derivatives of the indolone-N-oxide) showed the best antiplasmodial activity against Plasmodium berghei, 62% inhibition of the parasitaemia at 30 mg/kg/day.
Introduction
Because of multiple factors, the burden of malaria is currently increasing, the most important negative point being the development by P. falciparum (P.f. a ) of resistance to cheap and effective drugs like chloroquine (CQ). One of the innovative approaches to antimalarial drug discovery is based on the identification of new drug targets and attendant inhibitor design. However, as recently reviewed, 1-4 most of clinically available antimalarial drugs were developed using pregene technology-era pharmacochemical approaches and the action mechanisms for the majority have not as yet been clarified.
Our approach was to identify novel antimalarial synthetic molecules by focusing our strategy on a chemical substructural motif (scaffold) critical for parasite growth. In antimalarial activity of artemisinin-like compounds, 5 the endoperoxide group plays a key role. It is the validated chemical scaffold and, because this substructural motif is a reducible or a pro-oxidant group, it can also be called a redox pharmacophore. From the pharmacological point of view, other powerful reducible chemical groups may also be able to disrupt cellular redox homeostasis. In past decades, many mono-and di-N-oxides derivatives have been reported for their antimalarial activities. [6] [7] [8] [9] [10] In these chemical series, the N-oxide group could be identified as a reducible group.
Our interest in the nitrone group [CdN þ -O -] the chemical scaffold of radical spin traps led us to study the redox properties of some indolone derivatives. 11, 12 We observed that 2-alkyl-indolone-N-oxides 13 were rapidly reduced in solution, leading to radical nitroxide intermediates, while 2-aryl indolone-N-oxides were stable in solution. Moreover, they gave very stable spin adducts by trapping oxygen or carboncentered free radicals chemically or enzymatically produced. Previously, L. Lunazzi et al. 14 had also observed that under certain conditions, very long-lived radicals were generated via a proton attack from the solvent by heating up these indolones. Such chemical properties of N-oxide compounds were used to design bioreducible prodrugs such as tirapazamine derivatives with selective toxicity toward hypoxic cells. 15 This selectivity is based on the net reduction of the N-oxide moiety in the absence of oxygen, in a one or two-electron processapproach, by reductive enzymes. In addition, R. Danieli et al. 16 showed that indolone derivatives can be easily reduced by thiols. Recently, indazole N-oxide derivatives have been reported as antiprotozoal agents with a reduction mechanism. 17, 18 Moreover, antituberculosis or antimycobacterial activities have been reported for some indolone-Noxides. 19, 20 Considering indolone-N-oxide properties, we hypothesized that their capacities to be reduced and generate stable radical intermediates and their reactivity with thiols may be critical for parasite growth within red blood cells (RBC). RBCs contain high levels of reductases and reductants, such as glutathione, and display a decrease in molecular oxygen concentration and an increase in reactive oxygenated species during parasite maturation. The preliminary assays in vitro were highly promising.
We therefore undertook the synthesis and study of in vitro and in vivo antiparasitic activity against Plasmodium spp. of a series of indolone N-oxides ( Figure 1 ). We describe hereafter the synthesis and in vitro antiplasmodial activities assessed in CQsensitive (3D7), CQ-resistant (FcB1) and CQ and pyrimethamine cross-resistant (K1) strains of Plasmodium falciparum (P.f.). Hit optimization was carried out based on antiparasitic efficacy against the three strains, cytotoxicity against human cell lines, as well as physicochemical parameters. The study of in vivo activities was performed on Plasmodium berghei (NK65 and ANKA) murine models.
Chemistry
A series of 66 analogues of indolone N-oxides were prepared (Table 1) . Three synthetic pathways were considered and successfully used in this work, which led to the desired indolone N-oxide derivatives (i: compounds from 1 to 66) ( Figure 1 ). Method 1 is based on 1,2-diketone intermediates b, which are cyclized via nitro group reduction to generate the corresponding indolone N-oxides i. 11, 12 The 1,2-diketones were prepared by permanganate oxidation of a styrene precursor a, which is easily obtained by Wittig olefination of nitrobenzaldehydes with phosphonium ylides (Scheme 1). Method 2 21 is a one-pot procedure based on Sonogashira coupling of o-iodo nitro-aryles e with terminal alkynes f and concomitant cyclization of o-(arylalkynyl)-nitroaryles intermediates g into indolone N-oxides (Scheme 2). 22, 23 Method 3 derives from optimization of method 2 with the aim of improving yields, while increasing reaction kinetics. Specifically, method 3 was divided into two substeps: the first involved Sonogashira coupling as in method 2 as well as intermediate extraction, followed by an intramolecular cyclization using 4-dimethyl amino pyridine (4-DMAP) in refluxing pyridine (Scheme 3). [24] [25] [26] [27] In some cases, using AuBr 3 as catalyst accelerated the reaction rate and improved the yield. 28 It must be mentioned that several o-bromo-nitroaryles (e) and 1-alkynes (f) used in this study to prepare indolone N-oxide analogues were also of synthetic origin (Schemes 2, 3). Compounds e were obtained by electrophilic nitration of o-bromoaryles aldehydes using fuming nitric acid/acetic acid mixture. Synthesis of 1-alkynes (f) involved the preparation of 1-(trimethylsilyl)alkynes via Sonogashira coupling, followed by a desilylation step. Finally, O-benzyl-4-iodo-3-nitrophenol used to synthesize compounds 57 and 58 was obtained by O-benzylation of 4-iodo-3-nitrophenol (Scheme 4)
In comparing the methods used to synthesize indolone Noxides, it is worth pointing out that method 3 requires 0.5-17 h to prepare a target molecule, albeit of low (20-30%) chemical yields, whereas methods 1 and 2 may require 1-2 weeks. However, method 1 itself is of key importance when considering that some stable o-(alkylalkynyl)-nitroaryles intermediates g failed to spontaneously cyclize into indolone N-oxides under Sonogashira conditions. 24 To overcome difficulties in obtaining some targeted compounds according to previous methods, Sonogashira reactions were undertaken under microwave conditions; protocols were specifically adjusted for each reaction to obtain the expected compounds in a few minutes from low to moderate yield. Unfortunately, depending on the different substituents on aromatic rings, this easy protocol also failed in the synthesis of some designed indolones.
All of the compounds were chemically characterized by liquid chromatography (TLC and HPLC), infrared (IR), UV-visible, NMR ( 1 H and 13 C NMR), and mass spectrometry as well as elemental analysis. LogP values were calculated with VVCLAB software 29 and ranging between 0.62 and 4.79. Compound 57 is the most lipophilic in the series, and compound 51, the least one. It appeared that lipophilicity has no detrimental effect on antiplasmodial activity (Table 1) . Compounds were very poorly soluble in water except for salt forms (hydrochloride salt of the compounds 26, 28, and 30). Studies of compound stability in solution showed that the compounds were stable in aprotic solvents (CH 3 CN, (CH 3 ) 2 SO) and less stable in polar and protic solvents (MeOH, H 2 O) (data not shown).
Structure-Activity Relationship (SAR): Effect of Substituents on the Biological Activity. The compounds were designed according to the structure-activity relationship in considering the structure of the first hit identified, 1. In addition, commercial chemical libraries were examined and, according to their molecular profile, some compounds were selected for testing. These procedures were helpful in pharmacophore determinations. All prepared compounds were tested at the primary level on a CQ-resistant P. falciparum strain (FcB1). This initial step identified the substituent effects of the indolone-N-oxide at either position 2, 5, or 6 ( Figure 2 ). Figure 2 presents the basic structure of indolone-N-oxide derivatives. The phenyl group (A) of the indolone moiety was found to be essential for antiplasmodial activity. Replacement of the phenyl group (A) by either pyridine (N at position 4 of the indolone moiety, compound 66) or by pyridinium-N-oxide (N at position 5 of the indolone moiety, compound 65) led to significant activity loss, IC 50 was from 10-to 20-fold higher than their corresponding indolone analogue, compound 64.
As shown in Figure 3 , replacement of the phenyl group (R 3 ) (at position 2 of the indolone moiety) by an aliphatic chaine (n-propyl, 50, or i-butyl, 49) led to a significant loss of activity. Whereas functionalization of the phenyl moiety (R 3 ) by groups having a mesomeric effect (either þM: F, Cl, OCH 3 , OPh or -M: NO 2 ) improved the activity, while groups with inductive effect (either þI: CH 3 , C 2 H 5 , CH 2 OH or -I: CF 3 ) decreased the activity.
As shown in Figure 4 , comparable results were obtained with dioxymethylene derivatives of indolone-N-oxide, with the exception of compound 54 (IC 50 measured by LDH method, see Supporting Information). Figure 5 presents antiplasmodial activity of 2(4-methoxyphenyl)-indolone-N-oxide analogues. Substitutions at either position 5 or 6 of phenyl group (A) of the indolone moiety had no marked effect on IC 50 . Therefore, substitutions at R 3 affected antiplasmodial activity to a greater extent than substitutions at the phenyl group of the indolone moiety (cf. Figures 3 and 4 ). Figure 6 presents 5-methoxy-indolone-N-oxide analogues. Contrary to previous results (Figures 3, 4 ), substitutions at R 3 position had a slight effect on antiplasmodial activity, except when the substitution occurred at position 2 of the phenyl group (compounds: 43, 46). X-ray crystallographic studies of a similar compound (2-phenylisatogen) showed that isatogen and phenyl (R 3 ) rings were almost fully coplanar. 30 Hence substitution at position 2 led to a steric effect (hindrance) affecting the planarity system. Consequently, mesomeric-effect transmission from isatogen ring to phenyl ring would be inefficient due to low conjugation.
The conjugated system between nitrone group and ketonic function was found to be essential for an optimal in vitro antiplasmodial activity, while reduction of either nitrone or ketonic function led to a dramatic loss of activity (data not shown).
It was decided to analyze the possible capacity of the indolone-N-oxide derivatives to interact by stacking with heme. The malaria parasite does indeed break up hemoglobin inside RBC, releasing toxic-free heme. The parasite protects itself against heme toxicity by biocrystallizing around 30% of it into insoluble hemozoin. A compound that can inhibit this biocrystallization may be a potential antimalarial drug, as can the antimalarial chloroquine. The planarity of a molecule (conjugated system) may be indicative of a possible interaction with hemozoin. Several tests detecting such possible chemical drug/heme interaction are available. We used the assay developed by E. Deharo et al. 31 No relationship between antiplasmodial activity (IC 50 / FcB1) and heme-inhibiting polymerization capacity in the biochemical assay was found in a series of seven compounds (see Supporting Information).
Biology
In Vitro Antiplasmodial Activity against P. falciparum. Initial testing was carried out on a chloroquine (CQ)-resistant strain of P.f. (Table 1) . Several analogues displayed antiplasmodial activity in the low nanomolar range. Fourteen out of 66 synthetic compounds were found to be more potent in vitro against FcB1 than was chloroquine, with IC 50 s lower than 100 nM (Table 1) . Their cytotoxicity was evaluated on the MCF7 cell line. Selectivity index was defined as the ratio of CC 50 value in MCF7 cells to IC 50 value in CQ-resistant P.f. strain FcB1.
The best analogues, based on their selectivity index (SI > 200; MCF7/FcB1), were chosen for assays at the secondary level on a CQ-sensitive (3D7) and CQ and pyrimethamine-resistant (K1) strains of P.f. ( Table 2 ). All tested compounds were found to be more potent than CQ against K1 strain. Three of them showed lower IC 50 than that of artesunate against either 3D7 or K1 strains. Many compounds demonstrated equipotent activity against both CQsensitive and CQ-resistant strains. A comparison of IC 50 values between P.f.-resistant and sensitive strains suggested relatively low levels of cross-resistance to CQ. 32 Resistance index (RI) values, calculated from comparison of IC 50 values of resistant K1 or FcB1 and sensitive strains of P. falciparum 3D7 such as IC 50 (K1 or FcB1)/IC 50 (3D7), were found to be lower than those for CQ in the range 0.1-5.3 (K1) ( Table 2) . These compounds showed much lower resistance indices than those of CQ, suggesting that potential resistance to indolone structure is independent of chloroquine-resistance pathways.
Cytotoxicity assayed on mammalian MCF7 and KB cell lines were in the μmolar range. CC 50 values (MCF7) varied from 7.7 to 59.0 μM (Table 1 ) and from about 1 to 874 μM (KB) ( Table 2) . Most of the analogues tested at the secondary level had selectivity index greater than 200 (KB/3D7). Compounds that showed high selectivity (high selectivity index) are expected to offer the potential for safer therapy and constitute suitable candidates for further pharmacological studies.
In Vivo Antiplasmodial Activity against Plasmodium berghei. The best in vitro profiles displayed by indolone-N-oxide analogues, based on their potency, cytotoxicity, and selectivity index, led to the selection of some compounds for further in vivo evaluation against P. berghei strain. For compound 1, the parasitaemia clearance in vivo in P. berghei (NK65 strain) was 81% at 48 mg/kg in a 4-day test. No acute toxicity was observed in Swiss female mice at a dose of e140 mg/kg (Table 3) . Higher doses were not tested due to the lower solubility of the compound in DMSO at higher concentrations.
As shown in Table 4 , compound 1 had the best antiplasmodial activity by intraperitoneal (ip) route of administration, while it showed the lowest activity by the oral route of administration. This could be explained by the first-pass effect, which leads to an extensive degradation of compound 1 when administered by the oral route. These results were confirmed by the metabolic studies of these compounds within mouse liver microsomes ( Table 5) . Further details and protocols are available in the Supporting Information. Compound 1 has the lowest half-life time, whereas compound 4 has the highest one. Therefore, no significant difference was observed between the two administration routes (ip and po) for other compounds (4, 26, and 27).
Conclusion
The highest antiplasmodial activities were obtained for the 5-methoxy-indolone-N-oxide analogues (26, 27) . Compound 26 had the most potent antiplasmodial activity in vitro (<3 nM on FcB1 and=1.7 nM on 3D7) with a very satifactory selectivity index (CC 50 MCF7/IC 50 FcB1: > 14623; CC 50 KB/ IC 50 3D7: 198823).
Synthesis and screening of in vitro antiplasmodial activity and cytotoxicity of the novel series, indolone-N-oxide derivatives, identified promising antiplasmodial candidates based on their potency, selectivity index, and low cytotoxicity, rendering them as valid new leads for synthesizing new compounds that might improve the previous prototypes.
Materials and Methods
Commercial reagents were used as received without additional purification. Dichloromethane, acetonitrile, cyclohexane, and ethyl acetate were purchased from Fischer Bioblock (Strasbourg, France). Sodium sulfate, silica, silica gel 60 F-254 plates, ethanol, and methanol were purchased from VWR International (Strasbourg, France). Column chromatography for purification was carried out using 200-400 mesh chromagel. Flash chromatography was realized on CombiFlash (UVK-Lab. Toulouse, France). For molecular mass determination and purity control the following LC-PDA-MS n system was used (Thermo electron Corporation), including an automatic injector with oven (Spectra System AS3000), a degasser (Spectra System SCM1000), and a quaternary pump (Spectra System P1000 XR) coupled to a photodiode array detector PDA (Spectra System UV6000LP), and an ion trap mass spectrometer (Finnigan LCQ Deca XP Max), using nitrogen as a nebulizing and drying gas. Data acquisition was performed using Finnigan Xcalibur software (version 1.4). Chromatographic separation was performed using analytical columns either Thermo Hypersil Hyperprep RP C-18 (8 μm, 150 mm Â 4.6 mm) or Thermo BetaBasic RP C-4 (5 μm, 150 mm Â 4.6 mm). For data acquisition we also used Waters Millenium32 software, version 3.2 (Waters, St. Quentin, France). Other mass spectrometers were employed for molecular mass determination such as MS-Nermag R10-10 spectrometer using electron ionization (Service Commun Toulouse, France), and GCT 1er WATERS using electron ionization and desorption chemical ionization (Service Commun Toulouse, France) for high-resolution mass determination. Elemental analyses were done using Perkin-Elmer 2400 series II CHNS/O Elemental analyzer (LCC, Toulouse, France).
Compound purity was determined by HPLC-UV and LC-PDA-MS methods and was found in the range 96-99%. The 6 mmol) . NaOH aqueous solution (50%) (12.8 mmol) and tetrabutylammonium chloride (54 mmol) were then added. The mixture was stirred at room temperature until complete disappearance of the starting product. It was then extracted by dichloromethane; the organic phase was washed with brine and dried over anhydrous MgSO 4 and concentrated under reduced pressure. The crude material was purified by column chromatography (SiO 2 ) using dichloromethane as the eluant to give a mixture of E/Z-diastereoisomers. General Synthetic Procedure for Indolone N-Oxide Analogues (i). To a solution of diketone (0.59 mmol) in THF (10 mL) was added a 10% aqueous solution of NH 4 Cl (11 mL) and Zn (2.50 mmol). After 1 h of stirring at rt, the mixture was filtered, the two liquid phases separated, and the aqueous phase was extracted with dichloromethane. The combined organic phase was dried over anhydrous Na 2 SO 4 and concentrated under vacuum. The residue was dissolved in THF or dichloromethane (10 mL) and heated under reflux until complete disappearance of the intermediate hydroxylamine. After evaporation of the solvent, the crude product was purified by column chromatography (SiO 2 ) with toluene.
6-(4-Chlorophenyl)-7H- [1, 3] 4 mmol) were added. The mixture was stirred at room temperature for 5-7 days. The reaction mixture was filtered, the remaining solid was washed with ethyl acetate, and the combined solutions were evaporated to dryness, leaving an oily liquid. After solvent evaporation the crude product was purified by column chromatography (SiO 2 ). The product was then purified by recrystallization from toluene. , 2H) , sodium 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) (Sigma, Saint Quentin Fallavier, France) in water solution (0.5 mg/mL), and cells were incubated for 180 min. XTT was converted into a formazan product, detected at 450 nm. IC 50 values were determined graphically from dose-response curves (positive control being doxorubicin [Sigma]). Experiments were performed twice in triplicate Cytotoxicity was evaluated on KB cell line at a secondary level (London, UK). The AlamarBlue (Accumed International Inc., USA) method was used to assess cytotoxicity to the KB cell line. Microtiter plates were seeded at a density of 4 Â 10 4 KB cells/mL in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal calf serum (complete medium) (Seralab, Inc.) and incubated at 37°C, 5% CO 2 , 95% air mixture for 24 h, followed by compound addition to triplicate wells in a dilution series in complete medium. The positive control drug was podophyllotoxin (Sigma). Plates were incubated for a further 72 h, followed by the addition of 10 μL of Alamar-Blue (AccuMed International Inc.) to each well and incubation for 2-4 h at 37°C, 5% CO 2 , 95% air mixture. Fluorescence emission at 585 nm was measured in a SPECTRAMAX GE-MINI plate reader (Molecular Devices Inc.) after excitation at 530 nm. ED 50 values were calculated using XLFit (ID Business Solutions Ltd., UK) line fitting software. 6.7. In Vivo Assays. In vivo studies were approved by the appropriate institutional animal care and use committee.
The Primary Assay (Toulouse, France) with compound 1 of in vivo antimalarial efficacy was achieved using the P. berghei rodent malaria 4-day suppressive test. The compound was dissolved in 100% dimethyl sulfoxide (DMSO).
Animal and Conditions: mice, Swiss females, 20 ( 2 g; series: 10 animals per cage; control group: 10 animals; cages: standard; maintenance: conditioned air at 20°C and 50-60% relative humidity; diet with standard food and water ad libitum.
Test Procedure, Day 0: Heparinized blood was taken from a donor mouse with approximately 30% parasitaemia and diluted in physiological saline to 10 8 parasitized RBC per mL. An aliquot of 0.1 mL (10 7 parasitized RBC) of this suspension was injected intraperitoneally (ip) into experimental groups of 10 mice. Two h postinjection, the experimental groups were treated with a single dose of test compound, prepared in appropriate dilution in DMSO of the stock solution in DMSO, by intraperitoneally (ip) route; compound 1 was tested at six different doses. Day 1 to 3: 24, 48, and 72 h postinjection, the experimental group of mice were retreated again with the same dose and by the same route as on day 0.
Day 4: 24 h after the last treatment (i.e., 96 h postinjection), blood smears from all animals were prepared and stained with Giemsa. Parasitaemia was determined microscopically by counting 20 fields at approximately 100 RBC per field.
Activity was expressed as the difference between the mean value of the control group (taken as 100%) and those of the experimental group and calculated and expressed as percentage reductions (= activity) using the following equation:
activity ¼ 100 -mean -parasitemia -treated mean -parasitemia -control Â 100
Other Assays were made in LSHTM with similar protocols (London, UK).
Full Suppressive 4-Day Peters' Test: In vivo tests were performed under the UK Home Office Animals (Scientific Procedures) Act 1986. The rodent malaria line used was the P. berghei ANKA (drug-susceptible). Swiss outbred 20 g male CD-1 mice (Charles Rivers, UK), were kept in specific pathogen-free conditions and fed ad libitum. For oral administration, compounds were dissolved in standard suspending formula (SSV) [0.5% sodium carboxymethylcellulose, 0.5% benzyl alcohol, 0.4% Tween 80, 0.9% NaCl (all Sigma)]. For intraperitoneal administration, compounds were dissolved in 0.05% Tween 80. Mice were infected intravenously with 2 Â 10 6 infected red cells, randomized, and divided in groups of five mice for each dose (day 0). Oral treatment by gavage started 3 h postinfection and continued on day 1, 2, and 3 postinfection once a day. Parasitaemia was determined by microscopic examination of Giemsa stained blood films taken on day 4. Microscopic counts of blood films from each mouse were exported into a Microsoft Excel spreadsheet (Microsoft Corp.) and expressed as percentages of inhibition from the arithmetic mean parasitaemias of each group in relation to the untreated group. Dose-response curves were obtained and ED 50 and ED 90 values and 95% CI calculated using XLFit version 4 (ID Business Solutions Ltd., UK) line fitting software.
